Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity
In China, most normal BMI (body mass index of ≥18.5 to <25 kg/m2) adults with type 2 diabetes (T2DM) exhibit visceral adiposity. This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity. A total of 95 patients were randomized to receiv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2020/9783859 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387266189819904 |
|---|---|
| author | Xinlei Wang Xiaoqin Zhao Yunjuan Gu Xiaohui Zhu Tong Yin Zhuqi Tang Jin Yuan Wei Chen Rong OuYang Lili Yao Rongping Zhang Jie Yuan Ranran Zhou Yi Sun Shiwei Cui |
| author_facet | Xinlei Wang Xiaoqin Zhao Yunjuan Gu Xiaohui Zhu Tong Yin Zhuqi Tang Jin Yuan Wei Chen Rong OuYang Lili Yao Rongping Zhang Jie Yuan Ranran Zhou Yi Sun Shiwei Cui |
| author_sort | Xinlei Wang |
| collection | DOAJ |
| description | In China, most normal BMI (body mass index of ≥18.5 to <25 kg/m2) adults with type 2 diabetes (T2DM) exhibit visceral adiposity. This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity. A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks. Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were quantified by magnetic resonance imaging (MRI) and liver fat content (LFC) by liver proton magnetic resonance spectroscopy (1H MRS). Each patient’s weight, waist circumference, BMI, blood glucose, insulin sensitivity, pancreatic β-cell function, and fibroblast growth factor 21 (FGF-21) levels were measured. Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed. The change in 2 h plasma blood glucose was greater in the exenatide group (P=0.039). HOMA-IR and MBCI improved significantly after exenatide therapy (P<0.01, P=0.045). VAT and LFC decreased in both groups (P<0.01 for all) but to a greater extent in the exenatide group, while SAT only decreased with exenatide therapy (P<0.01). FGF-21 levels declined more in the exenatide group (P<0.01), but were positively correlated with VAT in the entire cohort before (r=0.244, P=0.043) and after (r=0.290, P=0.016) the intervention. The effects of exenatide on glycaemic metabolism, insulin resistance, pancreatic β-cell function, and fat deposition support its administration to normal BMI patients with T2DM and visceral adiposity. |
| format | Article |
| id | doaj-art-2f33b26663e445c8b348a17a699658fd |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-2f33b26663e445c8b348a17a699658fd2025-08-20T03:55:16ZengWileyJournal of Diabetes Research2314-67452314-67532020-01-01202010.1155/2020/97838599783859Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral AdiposityXinlei Wang0Xiaoqin Zhao1Yunjuan Gu2Xiaohui Zhu3Tong Yin4Zhuqi Tang5Jin Yuan6Wei Chen7Rong OuYang8Lili Yao9Rongping Zhang10Jie Yuan11Ranran Zhou12Yi Sun13Shiwei Cui14Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, ChinaIn China, most normal BMI (body mass index of ≥18.5 to <25 kg/m2) adults with type 2 diabetes (T2DM) exhibit visceral adiposity. This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity. A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks. Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were quantified by magnetic resonance imaging (MRI) and liver fat content (LFC) by liver proton magnetic resonance spectroscopy (1H MRS). Each patient’s weight, waist circumference, BMI, blood glucose, insulin sensitivity, pancreatic β-cell function, and fibroblast growth factor 21 (FGF-21) levels were measured. Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed. The change in 2 h plasma blood glucose was greater in the exenatide group (P=0.039). HOMA-IR and MBCI improved significantly after exenatide therapy (P<0.01, P=0.045). VAT and LFC decreased in both groups (P<0.01 for all) but to a greater extent in the exenatide group, while SAT only decreased with exenatide therapy (P<0.01). FGF-21 levels declined more in the exenatide group (P<0.01), but were positively correlated with VAT in the entire cohort before (r=0.244, P=0.043) and after (r=0.290, P=0.016) the intervention. The effects of exenatide on glycaemic metabolism, insulin resistance, pancreatic β-cell function, and fat deposition support its administration to normal BMI patients with T2DM and visceral adiposity.http://dx.doi.org/10.1155/2020/9783859 |
| spellingShingle | Xinlei Wang Xiaoqin Zhao Yunjuan Gu Xiaohui Zhu Tong Yin Zhuqi Tang Jin Yuan Wei Chen Rong OuYang Lili Yao Rongping Zhang Jie Yuan Ranran Zhou Yi Sun Shiwei Cui Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity Journal of Diabetes Research |
| title | Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity |
| title_full | Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity |
| title_fullStr | Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity |
| title_full_unstemmed | Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity |
| title_short | Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity |
| title_sort | effects of exenatide and humalog mix25 on fat distribution insulin sensitivity and β cell function in normal bmi patients with type 2 diabetes and visceral adiposity |
| url | http://dx.doi.org/10.1155/2020/9783859 |
| work_keys_str_mv | AT xinleiwang effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT xiaoqinzhao effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT yunjuangu effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT xiaohuizhu effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT tongyin effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT zhuqitang effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT jinyuan effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT weichen effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT rongouyang effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT liliyao effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT rongpingzhang effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT jieyuan effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT ranranzhou effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT yisun effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity AT shiweicui effectsofexenatideandhumalogmix25onfatdistributioninsulinsensitivityandbcellfunctioninnormalbmipatientswithtype2diabetesandvisceraladiposity |